Eli Lilly weight loss pill shows promise in latest clinical trial
In a news release Thursday, the drugmaker said the oral medication, called orforglipron, helped adults lose an average of 27.3 pounds in a 72-week trial.
The pill showed "significant efficacy, and a safety and tolerability profile consistent with injectable GLP-1 therapies," the release added.
The results shared by Eli Lilly, which have not been peer reviewed and published as of Thursday morning, are "on par with what we see with the injectable forms of these drugs," Dr. Céline Gounder, CBS News medical contributor and editor-at-large for public health at KFF Health News, said on "CBS Mornings" Thursday.
Some investors, however, were disappointed with the results Eli Lilly provided. Shares of the company were down about 13.9% Thursday morning.
Also like the injectables, the pill showed some side effects among participants, with the most commonly reported issues being nausea, vomiting, diarrhea and constipation.
"About 10% of people who are taking the highest dose, which is also what got you that high level of weight loss ... were unable to continue, had to stop, due to the side effects," Gounder said.
Eli Lilly said it is on track to submit orforglipron to regulatory agencies like the FDA for approval later this year, which means it could be available to consumers in 2026, Gounder said. It is unclear how much the drug will cost, but Gounder said she expected it to cost less than injectables.
A pill would be a "game changer" in terms of accessibility, she said.
"With the injectables, you need needles. You need to be able to refrigerate," she said. "What's great about the pills is it's a lot cheaper to manufacture a pill. It's a lot easier to take, and there are no restrictions around, you have to take it with water, with food. You can take it at any time of day. So this will make it a lot more accessible to people, both in terms of cost as well as convenience."
Earlier this year, orforglipron's efficacy and safety was measured in a trial with adults who have Type 2 diabetes, showing positive results.
Sneak peek: The Strange Shooting of Alex Pennig
Neil deGrasse Tyson weighs in on plans for a moon-based nuclear reactor
"Platonic" stars talk about new season and maintaining friendships as adults
Solve the daily Crossword
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
Quantum BioPharma Announces Very Promising Results from the Massachusetts General Hospital Scientists on the Novel Positron Emission Tomography (PET) Tracer Used to Detect and Monitor Demyelination in Multiple Sclerosis Patients
Ongoing Joint Clinical Study Could Pave the Way for Testing Efficacy of Quantum's Investigational MS drug, Lucid-21-302 TORONTO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ('Quantum BioPharma' or the 'Company'), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announces that the Positron Emission Tomography (PET) tracer used in a joint study with Massachusetts General Hospital (MGH) scientists shows the ability to capture differences across lesions in multiple sclerosis (MS) patients, which may prove highly useful for monitoring myelin integrity and demyelination in MS. A leading study by Drs. Pedro Brugarolas and Eric Klawiter of MGH, published in the European Journal of Nuclear Medicine and Molecular Imaging on August 5, 2025 (link to paper: and funded by the National Institutes of Health (NIH), evaluated the PET tracer [18F]3F4AP in healthy controls and in people with MS. This tracer was developed by Dr. Pedro Brugarolas, an investigator in the Department of Radiology at MGH and Assistant Professor at Harvard Medical School. In this study, [18F]3F4AP was found to have excellent properties for imaging the human brain and, critically and importantly, was able to detect differences across lesions not visible by conventional MRI. These findings suggest that the tracer holds significant promise and potential as a key biomarker to monitor changes in demyelination in MS, and, importantly, myelin changes in response to Quantum Biopharma's investigational and potentially breakthrough neuroprotective drug, Lucid-21-302. 'The published study shows that the PET tracer is highly promising as a biomarker to detect and monitor lesions in people with MS,' said Dr. Andrzej Chruscinski, Vice-President, Scientific and Clinical Affairs at Quantum Biopharma. 'The ongoing collaborative study with MGH seeks to further evaluate the imaging agent and its potential to demonstrate the effectiveness of drugs, such as Lucid-21-302 (Lucid-MS) that can protect the myelin sheath in MS.' About Quantum BioPharma Ltd. Quantum BioPharma (NASDAQ: QNTM) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. ('Lucid'), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented unbuzzd™ and spun out its OTC version to a company, Celly Nutrition Corp. ('Celly Nutrition'), now Unbuzzd Wellness Inc., led by industry veterans. Quantum BioPharma retains ownership of 20.10% (as of June 30, 2025) of Unbuzzd Wellness Inc. at The agreement with Unbuzzd Wellness Inc. also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum BioPharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. Quantum BioPharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property. For more information visit Forward Looking Information These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to additional information relating to Quantum BioPharma, including its annual information form, can be located on the SEDAR+ website at and on the EDGAR section of the United States Securities and Exchange Commission's website at for a more complete discussion of such risk factors and their potential effects. Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company's expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward- looking information, except as required by applicable law. Contacts: Quantum BioPharma Ltd. Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board Email: Zsaeed@ (833) 571-1811 Investor RelationsInvestor Relations: IR@ Inquiries: info@
Yahoo
16 minutes ago
- Yahoo
Tenaya Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya's Chief Executive Officer, will participate in the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025 at 11:30 am ET. The live webcast of the fireside chat may be accessed from the Investors section of Tenaya's website. An archived replay will be available on the Tenaya website for approximately 30 days following the live event. About Tenaya TherapeuticsTenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Tenaya's pipeline includes clinical-stage candidates TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM) and TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC). Tenaya has employed a suite of integrated internal capabilities, including modality agnostic target validation, capsid engineering and manufacturing, to generate a portfolio of novel medicines based on genetic insights, including TN-301, a clinical-stage small molecule HDAC6 inhibitor for the potential treatment of heart failure and related cardio/muscular disease, and multiple early-stage programs in preclinical development aimed at the treatment of both rare genetic disorders and more prevalent heart conditions. For more information, visit Tenaya ContactsMichelle CorralVP, Corporate Communications and Investor RelationsIR@ InvestorsAnne-Marie FieldsPrecision AQ in to access your portfolio
Medscape
17 minutes ago
- Medscape
Does Getting Fit Guard Against Colorectal Cancer?
Evidence continues to mount that building cardiovascular fitness can help lower an individual's risk for colorectal cancer (CRC). The latest study — a sweeping analysis of 643,583 individuals, with more than 8000 cases of CRC and 10 years follow-up — found a consistent, inverse, and graded association between cardiorespiratory fitness (CRF) and the risk for the development of CRC — a benefit similar for men and women and across races. CRC risk was 9% lower for each 1-metabolic equivalent (MET) task increase in CRF, objectively measured by an exercise treadmill test. When assessed across CRF categories, there was a progressive decline in CRC risk with higher CRF, Aamir Ali, MD, and colleagues with Veterans Affairs Medical Center, Washington, DC, found. Compared with the least fit individuals (METs, 4.8), the CRC risk was 14% lower in those falling in the low-fit CRF category (METs, 7.3), 27% lower for moderately fit people (METs, 8.6), 41% lower for fit individuals (METs, 10.5), and 57% lower for high-fit individuals (METs, 13.6). Moderate CRF is attainable by most middle-aged and older individuals, by engaging in moderate-intensity physical activity such as brisk walking, which aligns with current national guidelines, the authors said. The study was published online on July 28 in Mayo Clinic Proceedings. The results dovetail with earlier work. For example, in the Cooper Center Longitudinal Study, men with high mid-life CRF had a 44% lower risk for CRC and a 32% lower risk of dying from cancer later in life men with low CRF. A recent meta-analysis for the World Cancer Research Fund estimated a 16% lower risk for colon cancer in people with the highest levels of recreational physical activity relative to those with the lowest levels. A recent UK Biobank analysis using accelerometers linked higher daily movement to a 26% reduction in risk across multiple cancers, including bowel cancer. Taken together, the data suggest that 'the more you exercise, the better your overall health is going to be — not just your cardiac fitness but also your overall risk of cancer,' Joel Saltzman, MD, medical oncologist at Cleveland Clinic Taussig Cancer Center, Cleveland, noted in an interview with Medscape Medical News . Can You Outrun CRC Risk? In the US, CRC is the second leading cause of cancer mortality, accounting for 51,896 deaths in 2019. The economic burden of CRC in the US is significant, topping $24 billion annually. And while the incidence of colon cancer has decreased in older individuals during the past 3 decades, the incidence in younger adults has nearly doubled during the same period, 'underscoring the limitations of screening programs and the critical need for risk factor modification,' Ali and colleagues wrote. 'There is good evidence that exercise and healthy lifestyle/diet have significant benefit overall and as well for some potential risk reduction for colon cancer,' David Johnson, MD, professor of medicine and chief of gastroenterology, Eastern Virginia Medical School in Norfolk, Virginia, told Medscape Medical News. 'There are clearly suggestions of why this makes sense via the beneficial effects of exercise and physical activity in CRC pathways including but not limited to regulation of inflammation and aberrant cell growth/cancer pathways,' Johnson said. He emphasized, however, that exercise and lifestyle are not the best way to prevent CRC. 'Appropriate screening, in particular by colonoscopy (by skilled physicians who meet high-quality performance national benchmarks) to detect and remove precancerous polyps, is the best approach for prevention,' Johnson said. 'At this point — albeit exercise is potentially helpful and a great general recommendation — my most current advice as an expert in the field, is that you cannot outrun CRC risk,' Johnson said. Can You Outrun CRC Recurrence? Prevention aside, the data thus far are even more supportive of risk reduction for patients who have had CRC and are targeting reduction of recurrence, Johnson said. Perhaps the most compelling study was recently published in The New England Journal of Medicine. The CHALLENGE trial enrolled patients with resected stage II or III colon cancer who had completed their adjuvant chemotherapy. Patients with recurrences within a year of diagnosis were excluded, as they were more likely to have highly aggressive, biologically active disease. Participants were randomized to receive healthcare education materials alone or in conjunction with a structured exercise program over a 3-year follow-up period. The focus of the exercise intervention was increasing recreational aerobic activity over baseline by at least 10 METs — essentially the equivalent of adding about 45-60 minutes of brisk walking or 25-30 minutes of jogging three to four times a week. At a median follow-up of nearly 8 years, exercise reduced the relative risk for disease recurrence, new primary cancer, or death by 28% ( P = .02). 'This benefit persisted — and even strengthened — over time, with disease-free survival increasing by 6.4 and 7.1 percentage points at 5 and 8 years, respectively,' Johnson noted in a Medscape commentary. The CHALLENGE results are 'very compelling,' Bishal Gyawali, MD, PhD, associate professor of oncology at Queen's University, Kingston, Ontario, Canada, noted in a separate Medscape commentary. 'If you compare these results with results from other trials, you'll see that this is a no-brainer. If this were a drug, you would want to use it today,' Gyawali said. Saltzman told Medscape Medical News patients often ask him what they can do to help prevent their cancer from coming back. 'I would sort of say, 'Well, eat a healthy diet and exercise,' but I didn't have a lot of good evidence to support it.' The CHALLENGE study provides 'the proof in the pudding.' With these strong data, 'it almost feels like I should be able to write a prescription for my patient to join an exercise program and that their insurance should cover it,' Saltzman said.
